GlassScriptPhysician profile
Saul M Modlin
NPI 1013960210
$6,852.69
in general payments reported to CMS, 2019-2025
15 companies · $1,595 in 2025
The $1,595 reported for 2025 was more than what 87% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,469 · 2020: $156 · 2021: $468 · 2022: $958 · 2023: $458 · 2024: $749 · 2025: $1,595.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,398 · Travel and Lodging: $403.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,398.46 |
| Travel and Lodging | $402.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $1,340.98 | 2019 | |
| Genzyme Corporation | $941.83 | 2021-2025 | |
| Medical Device Business Services, INC. | $930.31 | 2019 | |
| Acclarent, INC | $668.86 | 2019-2024 | Acclarent Aera, Relieva Tract |
| Aerin Medical INC. | $621.85 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $582.71 | 2022-2025 | Dupixent |
| Neurent Medical Limited | $550.81 | 2025 | Neuromark Radiofrequency Console, Neuromark System |
| Glaxosmithkline, LLC. | $377.68 | 2023-2025 | Nucala |
| Inspire Medical Systems, INC. | $323.69 | 2023-2025 | Inspire |
| Genentech USA, INC. | $150.46 | 2024 | Xolair |
| Phathom Pharmaceuticals, INC. | $133.94 | 2024-2025 | Voquezna |
| Integra Lifesciences Corporation | $133.33 | 2025 | Relieva Spinplus Nav, Trudi Probe, Inspira Air |
| Optinose US, INC. | $46.65 | 2019 | |
| Merck Sharp & Dohme LLC | $35.90 | 2023 | Verquvo, Bridion |
| Merz North America, INC. | $13.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saul Modlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.